Evidence map›Paper›PMID 41103941›Full record

ArticleFrontiers in oncology2025

Personalized ICU mortality assessment by interpretable machine learning algorithms in patients with sepsis combined lung cancer: a population-based study and an external validation cohort.

Hongjie Tang, Hairong Hao, Yue Han

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hongjie TangDepartment of Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Hairong HaoDepartment of Endocrinology and Metabolism, Huai'an Hospital Affiliated to Xuzhou Medical University and Huai'an Second People's Hospital, Huai'an, Jiangsu, China.
Yue HanDepartment of Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Sepsis is a leading cause of mortality, especially among immunocompromised patients with lung cancer. We aimed to establish machine learning (ML) based model to accurately forecast ICU mortality in patients with sepsis combined lung cancer. Methods: We incorporated patients with sepsis combined lung cancer from Medical Information Mart for Intensive Care IV (MIMIC IV) database. Univariate and multivariate logistic analysis were employed to select variables. Recursive Feature Elimination (RFE) method based on 6 ML algorithms was used for feature selection. We harnessed 13 ML algorithms to construct prediction model, which were assessed by area under the curve (AUC), accuracy, sensitivity, specificity, precision, cross-entropy and Brier scores. The best ML model was constructed to predict ICU mortality, and the predictive results were interpretated by SHapley Additive exPlanations (SHAP) framework. Results: A sum of 1096 lung cancer patients combined sepsis from MIMIC IV database and 251 patients from the external validation set were included. We utilized 13 clinical variables to establish prediction model for ICU mortality. CatBoost model was identified as the prime prediction model with the highest AUC in the training (0.931 [0.921, 0.945]), internal validation (0.698 [0.673, 0.724]) and external validation (0.794 [0.725, 0.879]) cohorts. Oxford Acute Severity of Illness Score (OASIS) had the greatest influence on ICU mortality according to SHAP interpretation. Conclusions: Our ML models demonstrate excellent accuracy and reliability, facilitating more rigorous personalized prognostic forecast to lung cancer patients combined sepsis.

Indexed as

ICU mortalitylung cancermachine learningMIMIV-IVsepsis

Identifiers

PMID41103941
PMCPMC12522119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.